Table 2.
Demographic Characteristics Stratified by HLA Group
| Characteristic | Protective HLA |
Neither Protective nor Disease-Susceptible HLA |
Disease-Susceptible HLA-B*58:02 |
|||
|---|---|---|---|---|---|---|
| Vaccine (n = 12) | Placebo (n = 3) | Vaccine (n = 18) | Placebo (n = 13) | Vaccine (n = 7) | Placebo (n = 7) | |
| Age at enrollment, y | 25.5 (22.5–30.5) | 32 (22–32) | 22.5 (21.5–30.5) | 23 (22–26) | 22 (21–27) | 26 (21–34) |
| Sex | ||||||
| Female | 7 (58) | 3 (100) | 9 (50) | 10 (77) | 5 (71) | 5 (71) |
| Male | 5 (42) | 0 (0) | 9 (50) | 3 (23) | 2 (29) | 2 (29) |
| Circumcision statusa | ||||||
| Circumcised | 2 (40) | … | 5 (56) | 1 (33) | 0 (0) | 0 (0) |
| Uncircumcised | 3 (60) | … | 4 (44) | 2 (67) | 2 (100) | 2 (100) |
| Adenovirus 5 statusb | ||||||
| Seropositive | 9 (75) | 2 (67) | 17 (94) | 12 (92) | 6 (86) | 4 (57) |
| Seronegative | 3 (25) | 1 (33) | 1 (6) | 1 (8) | 1 (14) | 3 (43) |
| HSV-2 status at enrollment | ||||||
| Positive | 9 (75) | 2 (67) | 10 (56) | 5 (38) | 2 (29) | 5 (71) |
| Negative | 3 (25) | 1 (33) | 8 (44) | 8 (62) | 5 (71) | 2 (29) |
Data are no. (%) of subjects or median value (interquartile range). There were no significant differences between vaccine and placebo groups within each HLA subset for any characteristic.
Abbreviation: HSV-2, herpes simplex virus type 2.
a Data are for men circumcised at baseline or during study but before infection and those uncircumcised throughout study or before infection.
b Seropositivity was defined as a titer of >18, and seronegativity was defined as a titer of ≤18.